JAMA Neurology Author Interviews
by JAMA Network
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 11 chart positions in 11 markets.
By chart position
- 🇨🇦CA · Medicine#1245K to 30K
- 🇯🇵JP · Medicine#2830K to 100K
- 🇰🇷KR · Medicine#1451K to 10K
- 🇧🇷BR · Medicine#1471K to 10K
- 🇪🇸ES · Medicine#1881K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
27K to 106K🎙 Weekly cadence·124 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
53K to 212K🇯🇵47%🇨🇦14%🇻🇳14%+8 more - Active Followers
Loyal subscribers who consistently listen
16K to 64K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 11 epsHosts
Recent guests
Recent episodes
Gefurulimab and Generalized Myasthenia Gravis
Jul 27, 2026
Unknown duration
Acoustic Analysis of Primary Care Patient–Clinician Conversations to Screen for Cognitive Impairment
Jun 15, 2026
22m 40s
Phenoconversion in Pure Autonomic Failure
May 4, 2026
24m 01s
Brain Biomarkers and a Multidomain Lifestyle Intervention
Apr 20, 2026
22m 03s
Epstein-Barr Virus Antibodies and Multiple Sclerosis
Mar 9, 2026
14m 58s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/27/26 |  Gefurulimab and Generalized Myasthenia Gravis | Interview with Kelly G. Gwathmey, MD, author of Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis Gefurulimab—The First Effective Nanobody in Myasthenia Gravis Therapy | — | ||||||
| 6/15/26 | cognitive impairmentpatient-clinician conversations+3 | Joseph T. Colonel, PhD | JAMA Network | — | cognitive impairmentacoustic analysis+3 | — | 22m 40s | ||
| 5/4/26 | autonomic failureneurology+4 | Alessandra Fanciulli, MD, PhDEduardo de Pablo-Fernández, MD, PhD+2 | Phenoconversion in Pure Autonomic Failure: A Systematic Review and Meta-AnalysisPhenoconversion in Pure Autonomic Failure+1 | — | phenoconversionpure autonomic failure+5 | — | 24m 01s | ||
| 4/20/26 | brain biomarkerslifestyle intervention+3 | Susan M. Landau, PhD | Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention | — | brain biomarkerscognitive outcomes+3 | — | 22m 03s | ||
| 3/9/26 | Epstein-Barr VirusMultiple Sclerosis+3 | Hannes Vietzen | Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases | — | Epstein-Barr VirusMultiple Sclerosis+3 | — | 14m 58s | ||
| 2/9/26 | focal epilepsycomparative effectiveness+3 | Emanuele Cerulli Irelli, MD, PhD | Comparative Effectiveness of Brivaracetam, Cenobamate,Lacosamide, and Perampanel in Focal Epilepsy | — | BrivaracetamCenobamate+6 | — | 16m 59s | ||
| 11/24/25 | nervous system disordersglobal burden of disease+3 | John P. Ney, MD, MPH | Global Burden of Disease 2021 StudyUS Burden of Disorders Affecting the Nervous System | — | nervous systemdisorders+3 | — | 23m 33s | ||
| 10/6/25 | brain arteriovenous malformationshemorrhage risk+3 | Helen Kim, PhD | Risk of Future Hemorrhage From Unruptured Brain Arteriovenous Malformations: The Multicenter Arteriovenous Malformation Research Study (MARS) | — | brain AVMhemorrhage+3 | — | 16m 38s | ||
| 8/18/25 | mechanical thrombectomyclinical trial+3 | Colin P. Derdeyn, MD | Intravenous Argatroban or Eptifibatide in Patients Undergoing Mechanical Thrombectomy: A Subgroup Analysis of the MOST Randomized Clinical TrialIntravenous Argatroban or Eptifibatide in Patients Undergoing Mechanical Thrombectomy | — | argatrobaneptifibatide+5 | — | 19m 09s | ||
| 7/14/25 | idiopathic intracranial hypertensionGLP-1 receptor agonists+3 | Dennis J. Rivet II, MD | GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension | — | GLP-1 receptor agonistsidiopathic intracranial hypertension+3 | — | 22m 03s | ||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 6/2/25 | Multiple SclerosisRadiologically Isolated Syndrome+3 | Manuel Comabella, MD | Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome | — | Multiple SclerosisRadiologically Isolated Syndrome+3 | — | 14m 19s | ||
| 5/5/25 | migrainemajor depressive disorder+3 | Richard B. Lipton, MD | Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder | — | fremanezumabmigraine treatment+3 | — | 21m 13s | ||
| 3/31/25 |  Optimal Delay Time to Initiate Anticoagulation After AF-Associated Ischemic Stroke | Interview with Steven J. Warach, MD, PhD, author of Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Pragmatic, Response-Adaptive Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation | — | ||||||
| 3/3/25 |  Location and Timing of Recurrent, Nontraumatic Intracerebral Hemorrhage | Interview with David J. Seiffge, MD, author of Location and Timing of Recurrent, Nontraumatic Intracerebral Hemorrhage. Hosted by Cynthia E. Armand, MD. Related Content: Location and Timing of Recurrent, Nontraumatic Intracerebral Hemorrhage | — | ||||||
| 1/6/25 |  Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine | Interview with Wei-Hsuan Lo-Ciganic, PhD, author of Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine. Hosted by Cynthia E. Armand, MD. Related Content: Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine | — | ||||||
| 12/2/24 |  β-Blocker Use and Delayed Onset and Progression of Huntington Disease | Interview with Jordan L. Schultz, PharmD, author of β-Blocker Use and Delayed Onset and Progression of Huntington Disease. Hosted by Cynthia E. Armand, MD. Related Content: β-Blocker Use and Delayed Onset and Progression of Huntington Disease | — | ||||||
| 11/1/24 |  Alzheimer Disease as a Clinical-Biological Construct | Interview with Giovanni B. Frisoni, MD, author of Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation. Hosted by Cynthia E. Armand, MD. Related Content: Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation | — | ||||||
| 9/23/24 |  Perceived CTE in Former Professional Football Players | Interview with Rachel Grashow, PhD, MS, and Aaron L. Baggish, MD, authors of Perceived Chronic Traumatic Encephalopathy and Suicidality in Former Professional Football Players. Hosted by Cynthia E. Armand, MD. In the US, you can call, text, or chat 988, the Suicide and Crisis Lifeline. Related Content: Perceived Chronic Traumatic Encephalopathy and Suicidality in Former Professional Football Players | — | ||||||
| 8/19/24 |  Localized Nicardipine Release Implants for Prevention of Vasospasm | Interview with Peter Vajkoczy, MD, author of Localized Nicardipine Release Implants for Prevention of Vasospasm After Aneurysmal Subarachnoid Hemorrhage: A Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Localized Nicardipine Release Implants for Prevention of Vasospasm After Aneurysmal Subarachnoid Hemorrhage | — | ||||||
| 7/8/24 |  Direct-Acting OACs and Antiseizure Medications for AF and Epilepsy and Risk of Thromboembolic Events | Interview with Allison W. Willis, MD, MS, author of Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events. Hosted by Cynthia E. Armand, MD. Related Content: Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events | — | ||||||
| 5/28/24 |  Early vs Late Anticoagulation in Minor, Moderate, and Major Ischemic Stroke With Atrial Fibrillation | Interview with Urs Fischer, MD, MSc, author of Early vs Late Anticoagulation in Minor, Moderate, and Major Ischemic Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Early vs Late Anticoagulation in Minor, Moderate, and Major Ischemic Stroke With Atrial Fibrillation | — | ||||||
| 4/29/24 |  Association of New-Onset Seizures With SARS-CoV-2 Vaccines | Interview with Churl-Su Kwon, MD, MPH, author of Association of New-Onset Seizures With SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Hosted by Cynthia E. Armand, MD. Related Content: Association of New-Onset Seizures With SARS-CoV-2 Vaccines | — | ||||||
| 3/25/24 |  High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS | Interview with Anne Kerbrat, MD, PhD, author of High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS. Hosted by Cynthia E. Armand, MD. Related Content: High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS | — | ||||||
| 2/26/24 |  Posttraumatic Epilepsy and Dementia Risk | Interview with Andrea L. C. Schneider, MD, PhD, author of Posttraumatic Epilepsy and Dementia Risk. Hosted by Cynthia E. Armand, MD. Related Content: Posttraumatic Epilepsy and Dementia Risk | — | ||||||
| 2/5/24 |  Risk of Stroke and Myocardial Infarction Among Initiators of Triptans | Interview with Jesper Hallas, MD, DMSc, author of Risk of Stroke and Myocardial Infarction Among Initiators of Triptans. Hosted by Cynthia E. Armand, MD. Related Content: Risk of Stroke and Myocardial Infarction Among Initiators of Triptans | — | ||||||
Showing 25 of 128
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for JAMA Neurology Author Interviews
Peaked at #28 in Japan, currently #28 in Japan.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| Japan | — | #28 | #28 | — |
| VN | — | #44 | #44 | — |
| ID | — | #56 | #56 | — |
| Canada | — | #124 | #124 | — |
| TW | — | #134 | #134 | — |
| New Zealand | — | #144 | #144 | — |
| South Korea | — | #145 | #145 | — |
| Brazil | — | #147 | #147 | — |
| TH | — | #156 | #156 | — |
| CL | — | #167 | #167 | — |
| Spain | — | #188 | #188 | — |
Chart Positions
11 placements across 11 markets.
Chart Positions
11 placements across 11 markets.